Live
Clinical OMICsSignatera™ as a Pan-Cancer Decision-Making Tool to Illuminate the Care PathwayEndpoints NewsGoHealth files for bankruptcy, as Medicare Advantage insurers pull backAgilentHow Investors May Respond To Agilent Technologies (A) Expanding AI-Enabled Lab Solutions And Oncology Diagnostics - simplywall.stBioPharma DiveTango data add to growing momentum for pancreatic cancer drugsBioWorldAppointments and advancements for June 8, 2026BioWorldFinancings for June 8, 2026BioWorldIn the clinic for June 8, 2026BioWorldOther news to note for June 8, 2026BioWorldRegulatory actions for June 8, 2026Thermo FisherThermo Fisher Scientific Introduces New Mass Spectrometry Platforms and AI Software - Clinical Lab ProductsBioPharma DiveIncyte to buy blood disorder drug in possibly $2B dealFierceBiotechClinical-stage cancer biotech Treeline sees path to public markets via reverse merger
Endpoints News 18 déc. 2025

Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting

Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting

Original
Contenu indisponible. Consultez la source originale.